

1 **Title**  
2 Wide variability in colorectal cancer screening uptake by general practitioner: cross-sectional study  
3

4 **Short title**  
5 Colorectal screening uptake variability by GP.  
6

7 **Authors**  
8 Cecilia Acuti Martellucci<sup>1\*</sup>, MHS, Maria Elena Flacco<sup>1\*</sup>, MD, Margherita Morettini<sup>2</sup>, MD, Giusi  
9 Giacomini<sup>2</sup>, MD, Matthew Palmer<sup>3</sup>, MPH, Stefania Fraboni<sup>2</sup>, Francesca Pasqualini<sup>2</sup>, MD  
10

11 **Affiliations**  
12 <sup>1</sup> Department of Medical Sciences, University of Ferrara, Italy  
13 <sup>2</sup> Oncologic Screening Department, Hygiene and Public Health Service, Area 2 of the Regional Health  
14 Agency of the Marche Region, Italy  
15 <sup>3</sup> Melbourne School of Population and Global Health, The University of Melbourne, Melbourne,  
16 Victoria, Australia  
17 \*These authors contributed equally to the present study.  
18

19 **Corresponding author**  
20 Cecilia Acuti Martellucci  
21 Department of Medical Sciences, Università degli Studi di Ferrara, Via Fossato di Mortara 64/B  
22 44121 Ferrara, Italy  
23 [cecilia.martellucci@unife.it](mailto:cecilia.martellucci@unife.it)  
24 <https://orcid.org/0000-0002-4308-2144>  
25

26 **Abstract word count**  
27 245  
28

29 **Word count**  
30 1783

1 **Abstract**

2

3 **Objectives:** Despite several interventions, colorectal cancer (CRC) screening uptake remains below  
4 acceptable levels in Italy. Among the potential determinants of screening uptake, only a few studies  
5 analyzed the role of general practitioners (GPs). The aim was to evaluate the variation in screening  
6 uptake of the clusters of subjects assisted by single GPs.

7 **Setting:** Ancona province, Central Italy.

8 **Methods:** Cross-sectional study, including all residents aged 50-69 years, who were offered the public  
9 screening programme with biannual faecal immunochemical tests. Demographic (of all GPs) and  
10 screening data (of all eligible residents) for years 2018-19 were collected from the official electronic  
11 datasets of the Ancona Local Health Unit. The potential predictors of acceptable screening uptake,  
12 including GP's gender, age, and number of registered subjects, were evaluated using random-effect  
13 logistic regression, with geographical area as the cluster unit.

14 **Results:** The final sample consisted of 332 GP clusters, including 120,178 eligible subjects. The  
15 overall province uptake was 38.0%±10.7%. The uptake was lower than 30% in one fifth of the GP  
16 clusters, and higher than 45% in another fifth. At multivariable analysis, the significant predictors of  
17 uptake were younger GP age ( $p=0.010$ ) and lower number of registered subjects ( $p<0.001$ ). None of  
18 the GP clusters with 500 subjects or more showed an uptake  $\geq 45\%$ .

19 **Conclusions:** The wide variation across GPs suggests they might substantially influence screening  
20 uptake, highlighting a potential need to increase their commitment to CRC screening. Further research  
21 is needed to confirm the role of the number of registered subjects.

22

23 **Keywords:** Colorectal cancer, cancer screening, general practice, Italy.

24

25

1 **Introduction**

2 In Italy, almost 50,000 new cases of colorectal cancer (CRC) are diagnosed yearly.(1) Screening  
3 programmes are effective in reducing CRC burden,(2) and they have thus been recommended in all  
4 Italian provinces since 2001, with most programmes using the faecal immunochemical test (FIT).(3)  
5 The screening uptake of many programmes, however, is still below the 45% acceptability threshold  
6 set by the Italian Group for Colorectal Cancer Screening (GISCoR).(4, 5)

7 Several interventions have been attempted to increase the uptake, such as mass educational campaigns,  
8 mailing FIT kits, providing reminders, and promotion through general practitioners (GPs).(6, 7)

9 Although GPs' advice has been associated with higher CRC screening uptake,(8, 9) and all Italian GPs  
10 are trained to promote cancer screening, GPs' potential impact on CRC screening uptake remains  
11 largely undetermined.(7, 10) Indeed, only one similar study was performed in Italy on data from  
12 2006-2012, and more recently one in Switzerland, both of which showed large differences in uptake  
13 of CRC screening according to the GP. (11, 12)

14 In order to provide an updated assessment of the potential impact of GPs on CRC screening uptake,  
15 we performed a cross-sectional study to assess the extent of variation in uptake among the clusters of  
16 subjects registered with different GPs.

17

18 **Methods**

19 In the province of Ancona, Central Italy, the CRC screening programme uses FIT and is  
20 recommended free of charge for all citizens aged 50-69 years, every two years. The programme is  
21 managed by the Local Health Unit, which regularly sends letter invitations to all eligible subjects. The  
22 letter contains the signature of the Director of the Screening Programme, and also that of each  
23 person's GP, as suggested by national guidelines in order to improve the programme's reliability. In  
24 the province, all pharmacies distribute FIT vials, 34 collection points are available for vial collection,  
25 and one laboratory analyzes the specimens (Figure 1).

26 All data are referred to the years 2018-19 and have been obtained from the cancer screening software  
27 of the Local Health Unit of Ancona. For all GPs of the province, we retrieved individual data on age,  
28 gender, geographic location of the office, number of registered subjects who participated in CRC

1 screening, and total number of registered subjects who were eligible for screening participation.  
2 Individual data of eligible subjects was not available, only the proportion participating for each  
3 practice was obtained. GPs with less than 20 eligible registered subjects, or retired during the study  
4 period, were excluded from the analyses. Registered subjects are those individuals that are followed  
5 and assisted by a single GP, who, in turn, is in charge of the primary healthcare of all the patients  
6 registered into his/her list. Assuming a two-tailed p-value of 0.05, the main analysis, based upon a  
7 total of 199 GPs aged 61 years or more, and 133 GPs aged up to 60 years, with average screening  
8 uptakes of 36.5% (SD 8.3%) and 40.1% (13.2%), respectively, had a statistical power of 79% to  
9 detect significant differences in registered patients screening uptake between GPs aged 61 years or  
10 more, vs GPs aged up to 60 years.

11 We computed the CRC screening uptake separately for each cluster of subjects registered with single  
12 GPs.(13) First, Student's t tests were used to evaluate uptake according to GPs' characteristics. In  
13 order to explore the possible determinants of uptake variability across GP clusters, we evaluated the  
14 potential independent association between uptake and GPs' gender, age (continuous), and number of  
15 registered subjects (continuous), using random-effects linear regression. Additionally, we evaluated  
16 the potential independent association between reaching the 45% uptake acceptability threshold and  
17 GPs' gender, age (60 years or younger, over 60), and number of registered subjects (<250, 250-349,  
18 350-449,  $\geq 450$ ), using random-effects logistic regression. For both models, geographical area was  
19 used as the cluster unit, and all the other recorded variables were included a priori.(14) Statistical  
20 significance was defined as a two-sided p-value<0.05 for all analyses, which were performed using  
21 Stata 15.1 (Stata Corp., College Station, TX, USA, 2017).

22

## 23 **Results**

24 The final sample consisted of 332 GPs' clusters, including a total of 120,178 subjects eligible for CRC  
25 screening in the years 2018-19 (mean cluster size: 362). The mean uptake of these clusters was 38.0%  
26 (standard deviation: 10.7%; Table 1). The uptake largely varied across clusters, ranging from a  
27 minimum of 6.9%, up to a maximum of 76.5%. Out of all the GP clusters, 12 (3.6%) showed an

1 uptake below 20%, and 68 (20.5%) showed an uptake below 30%. Only 67 clusters (20.2%) achieved  
2 an uptake of 45% or more (Figure 2).

3 The mean uptake varied significantly by GPs' age (36.5% and 40.1%, respectively, in the clusters  
4 registered with GPs aged >60 and ≤60 years; p=0.003), geographical area (33.5% and 43.7%,  
5 respectively, in the clusters from Ancona and Jesi; p<0.001), and number of registered subjects  
6 (34.3% and 41.5%, respectively, in the clusters with ≥450 and <250 eligible subjects; p=0.002) (Table  
7 1), with an uptake lower than 45% in all of the clusters including 500 subjects or more  
8 (Supplementary Figure 1).

9 Multivariable analysis substantially confirmed univariate results (Table 2): uptake was significantly  
10 and independently associated with younger GP's age (+4.8% for a 10-year decrease; 95% Confidence  
11 Intervals - CI: 3.7%-5.9%), and smaller cluster size (+1.5% for a 100-subject decrease; 95% CI:  
12 0.4%-2.6%). Finally, concerning the uptake acceptability threshold, GPs aged over 60 years had Odds  
13 Ratio - OR 0.47 (Confidence Interval 0.27-0.84) of reaching this threshold, compared to the younger  
14 ones. Also, those with 450 or more registered eligible subjects had OR 0.16 (CI 0.07-0.37) of reaching  
15 the same acceptability threshold, compared to the GPs with less than 250 subjects, (Table 3). No  
16 significant differences in screening uptake were observed by GP's gender.

17

## 18 **Discussion**

19 Overall, during the 2018-19 biennium, in a province of Central Italy, we observed wide variations in  
20 CRC screening uptake between clusters of citizens registered with different GPs: about one fifth of  
21 the clusters showed an uptake lower than 30%, while only another fifth showed the acceptable uptake  
22 of 45%. After adjusting for GP's gender and geographical area, the clusters of younger GPs, with less  
23 registered subjects, showed a significantly higher screening uptake.

24

25 This study offers evidence on a scarcely explored subject, namely the impact of GPs on uptake of  
26 CRC screening, and it is the first, in Italy, to assess the possible role of GPs' target population  
27 size.(15) The screening database provided official certified data on the entire resident population, with

1 a very low (<5%) proportion of privately performed FIT which was missed. Also, although  
2 monocentric, this study included a large sample of over 120,000 subjects registered with GPs.  
3 The study has also some limitations that must be considered. First, no individual-level determinants of  
4 screening, such as socio-economic status, were available for the subjects registered with the GPs.  
5 However, within the province of Ancona, it is unlikely that the differences across GP clusters were  
6 large enough to explain the observed wide variation in screening uptake.(16, 17) Moreover, the large  
7 number of clusters minimizes the chances of potential differences being unbalanced in the overall  
8 sample. Another limitation is the small number of GP-level variables, preventing the assessment of  
9 potential determinants of screening uptake beyond gender, age, and cluster size. Finally, the cross-  
10 sectional design did not allow inferring causal relationships.

11

12 With regard to the observed wide variations in CRC screening uptake across GP clusters, only one  
13 Italian study analysed the uptake in 320,534 subjects registered with GPs in Perugia in 2006-08 and  
14 2011-12, with both GPs and geographical areas as cluster units, and found similarly broad differences  
15 among GP clusters (range 21%-57%).(11) Even larger variations across GPs (range 0%-91%) were  
16 found in a 2017 Swiss study including 3451 subjects.(12)

17 The finding of an inverse association between uptake and the number of patients registered with GPs  
18 is in line with the only Italian study available to date: in the Lazio Region, the GPs visiting more than  
19 25 patients per day showed a 26% lower screening uptake compared to those visiting less  
20 patients.(13) In contrast, a study from Wisconsin, USA, reported a positive association between a  
21 larger number of eligible registered individuals and screening uptake.(18) However, this study was  
22 performed within a collaborative of healthcare providers and purchasers committed to improving  
23 healthcare quality, where specific enabling factors, incentives, or controls might have increased CRC  
24 screening uptake.(18) In fact, in the province of Ancona there was no system motivating GPs to  
25 promote CRC screening.

26 Also the observation of a lower mean uptake in the metropolitan area (Ancona) is in agreement with  
27 one Italian National study,(19) and a study from England, where London was the area with the lowest  
28 uptake.(20) However, one study from USA and one from Australia found the lowest uptake in rural

1 communities.(21, 22) Indeed, it is plausible that the provision of cancer screening could differ  
2 substantially in rural areas of European countries, as opposed to rural areas of countries with lower  
3 population density, where remoteness may represent a very large barrier to healthcare.(23)  
4 Finally, our observation of a higher uptake in clusters of younger GPs contrasts with the articles cited  
5 above from Italy, Switzerland, and Wisconsin, which found no association between GPs' age and  
6 uptake.(12, 15, 18) While these three studies included less than 100 GPs, and therefore could have  
7 been underpowered to assess this association, it cannot be excluded that the determinants associated  
8 with CRC screening uptake, such as cluster size and GPs' age, might be context-specific.(12, 15, 18)

9

10 A variety of interventions involving GPs, or 'regular doctors', have been designed to improve CRC  
11 screening uptake: the most common are GP endorsement of screening invitations, sending reminders  
12 to both patients and GPs (lists of registered persons not adhering to the screening), providing FIT kits  
13 at physicians' offices, or distributing printed screening advice.(24-28) Of these, GP endorsement of  
14 the invitation to CRC screening, as well as point-of care FIT kits provision, were shown to produce  
15 substantial improvements in uptake, while scarce evidence is available in support of reminders to GPs  
16 and distribution of printed material.(24-29)

17 In the province of Ancona, the GP's signature is already present on invitation letters, and therefore the  
18 detected variations in uptake may be concerning, suggesting the need to increase the commitment of  
19 the GPs to CRC screening. In the area under investigation, the policies may prioritize older GPs and  
20 those with larger clusters. Further research is needed to determine whether the observed variations are  
21 common in other areas, as well as to confirm the influence of the age of GPs and of the number of  
22 citizens registered with each GP on CRC screening uptake. Also, future studies are required to  
23 interview older and younger GPs, as well as those with larger and smaller populations, to better  
24 understand why these populations have higher or lower screening participation, what the GPs are  
25 doing differently in relation to CRC screening promotion, and their perceived role.

26

27 **Funding:** None.

28

1 **Ethical Approval:** The study was approved by the Ethics Committee of the Marche Region on April  
2 1<sup>st</sup> 2020, with number 2020-84.

3

4 **Declaration of Conflicting Interests:** The authors declare that there is no conflict of interest.

5

6 **Data availability:** The data that support the findings of this study are available from the  
7 corresponding author upon reasonable request.

8

9

## 10 **References**

- 11 1. AIRTUM, AIOM. I numeri del cancro in Italia. 2019.
- 12 2. European Colorectal Cancer Screening Guidelines Working G, von Karsa L, Patnick J,  
13 Segnan N, Atkin W, Halloran S, et al. European guidelines for quality assurance in colorectal cancer  
14 screening and diagnosis: overview and introduction to the full supplement publication. *Endoscopy*.  
15 2013;45(1):51-9.
- 16 3. Government I. Decree November 29 2001 (DPCM). Definition of basic assistance levels.  
17 Rome2011.
- 18 4. Zorzi M, Da Re F, Mantellini P, Naldoni C, Sassoli de' Bianchi P, Senore C, et al. Screening  
19 for colorectal cancer in Italy:2011-2012 survey. *Epidemiol Prev* 2015;39 (3):1-125.
- 20 5. Zorzi M, de' Bianchi PS, Grazzini G, Senore C. [Quality indicators for the evaluation of  
21 colorectal cancer screening programmes]. *Epidemiol Prev*. 2007;31(6 Suppl 1):6-56.
- 22 6. Giorgi Rossi P, Camilloni L, Cogo C, Federici A, Ferroni E, Furnari G, et al. Health  
23 Technology Assessment - Methods to increase participation in cancer screening programmes.  
24 *Epidemiol Prev*. 2012;36:1-109.
- 25 7. Italian Ministry of Health. [Technical document to reduce the burden of disease due to cancer  
26 for 2011-13]. Rome2010. p. 122.
- 27 8. Hadjipetrou A, Anyfantakis D, Galanakis CG, Kastanakis M, Kastanakis S. Colorectal cancer,  
28 screening and primary care: A mini literature review. *World J Gastroenterol*. 2017;23(33):6049-58.



- 1 9. Bocci G, Troiano G, Messina G, Nante N, Civitelli S. Factors that could influence women's  
2 participation in colorectal cancer screening: an Italian study. *Ann Ig.* 2017;29(2):151-60.
- 3 10. Dodd N, Mansfield E, Carey M, Oldmeadow C, Sanson-Fisher R. Have we increased our  
4 efforts to identify strategies which encourage colorectal cancer screening in primary care patients? A  
5 review of research outputs over time. *Prev Med Rep.* 2018;11:100-4.
- 6 11. Stracci F, Gili A, Naldini G, Gianfredi V, Malaspina M, Passamonti B, et al. Geospatial  
7 analysis of the influence of family doctor on colorectal cancer screening adherence. *PLOS ONE.*  
8 2019;14(10):e0222396.
- 9 12. Braun AL, Prati E, Martin Y, Dvorak C, Tal K, Biller-Andorno N, et al. Variation in  
10 colorectal cancer testing between primary care physicians: a cross-sectional study in Switzerland. *Int J*  
11 *Public Health.* 2019;64(7):1075-83.
- 12 13. European Commission. European guidelines for quality assurance in colorectal cancer  
13 screening and diagnosis. 1st ed. Luxembourg; 2010 2010.
- 14 14. Flacco ME, Manzoli L, Bucci M, Capasso L, Comparcini D, Simonetti V, et al. Uneven  
15 Accuracy of Home Blood Pressure Measurement: A Multicentric Survey. *The Journal of Clinical*  
16 *Hypertension.* 2015;17(8):638-43.
- 17 15. Federici A, Giorgi Rossi P, Bartolozzi F, Farchi S, Borgia P, Guastecchi G. The role of GPs in  
18 increasing compliance to colorectal cancer screening: a randomised controlled trial (Italy). *Cancer*  
19 *Causes Control.* 2006;17(1):45-52.
- 20 16. I.Stat - Income by municipality, years 2016-2018 [Internet]. 2020 [cited October 5 2020].  
21 Available from: [http://dati.istat.it/index.aspx?lang=en&SubSessionId=cd70349a-ab9f-46ff-a5b6-](http://dati.istat.it/index.aspx?lang=en&SubSessionId=cd70349a-ab9f-46ff-a5b6-1502a9b98b32)  
22 [1502a9b98b32](http://dati.istat.it/index.aspx?lang=en&SubSessionId=cd70349a-ab9f-46ff-a5b6-1502a9b98b32).
- 23 17. Ambrogiani E, Capezzone G, Cimini D, Fiacchini D, Guidi A, Morbidoni M, et al. [Health  
24 profile of the Ancona Province population - 2014]. Ancona: Healthcare Agency of the Marche  
25 Region; 2014 February 2015.
- 26 18. Weiss JM, Smith MA, Pickhardt PJ, Kraft SA, Flood GE, Kim DH, et al. Predictors of  
27 Colorectal Cancer Screening Variation Among Primary-Care Providers and Clinics. *American Journal*  
28 *of Gastroenterology.* 2013;108(7):1159-67.

- 1 19. Giorgi Rossi P, Carrozzi G, Federici A, Mancuso P, Sampaolo L, Zappa M. Invitation  
2 coverage and participation in Italian cervical, breast and colorectal cancer screening programmes.  
3 *Journal of Medical Screening*. 2017;25(1):17-23.
- 4 20. Hirst Y, Stoffel S, Baio G, McGregor L, von Wagner C. Uptake of the English Bowel  
5 (Colorectal) Cancer Screening Programme: an update 5 years after the full roll-out. *Eur J Cancer*.  
6 2018;103:267-73.
- 7 21. Wang H, Roy S, Kim J, Farazi PA, Siahpush M, Su D. Barriers of colorectal cancer screening  
8 in rural USA: a systematic review. *Rural Remote Health*. 2019;19(3):5181.
- 9 22. Goodwin BC, March S, Ireland M, Crawford Williams F, Manksi D, Ford M, et al.  
10 Geographic variation in compliance with Australian colorectal cancer screening programs: the role of  
11 attitudinal and cognitive traits. *Rural Remote Health*. 2019;19(3):4957.
- 12 23. Rechel B, Džakula A, Duran A, Fattore G, Edwards N, Grignon M, et al. Hospitals in rural or  
13 remote areas: An exploratory review of policies in 8 high-income countries. *Health policy*  
14 (Amsterdam, Netherlands). 2016;120(7):758-69.
- 15 24. Sequist TD, Zaslavsky AM, Marshall R, Fletcher RH, Ayanian JZ. Patient and physician  
16 reminders to promote colorectal cancer screening: a randomized controlled trial. *Arch Intern Med*.  
17 2009;169(4):364-71.
- 18 25. Cole SR, Young GP, Byrne D, Guy JR, Morcom J. Participation in screening for colorectal  
19 cancer based on a faecal occult blood test is improved by endorsement by the primary care  
20 practitioner. *J Med Screen*. 2002;9(4):147-52.
- 21 26. Dodd N, Carey M, Mansfield E, Oldmeadow C, Evans TJ. Testing the effectiveness of a  
22 general practice intervention to improve uptake of colorectal cancer screening: a randomised  
23 controlled trial. *Aust N Z J Public Health*. 2019;43(5):464-9.
- 24 27. Rat C, Pogu C, Le Donne D, Latour C, Bianco G, Nanin F, et al. Effect of Physician  
25 Notification Regarding Nonadherence to Colorectal Cancer Screening on Patient Participation in  
26 Fecal Immunochemical Test Cancer Screening: A Randomized Clinical Trial. *Jama*. 2017;318(9):816-  
27 24.

1 28. Hewitson P, Ward AM, Heneghan C, Halloran SP, Mant D. Primary care endorsement letter  
2 and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial  
3 randomised trial. *British Journal of Cancer*. 2011;105(4):475-80.

4 29. Rat C, Latour C, Rousseau R, Gaultier A, Pogu C, Edwards A, et al. Interventions to increase  
5 uptake of faecal tests for colorectal cancer screening: a systematic review. *European journal of cancer  
6 prevention : the official journal of the European Cancer Prevention Organisation (ECP)*.  
7 2018;27(3):227-36.

8

1  
2  
3

**Table 1.** CRC screening uptake across GP clusters, overall and by selected GP's characteristics. Years 2018-19.

GP characteristics	Number of GP clusters	Number of eligible subjects	Mean uptake (SD), %	p*
Overall sample	332	120,178	38.0 (10.7)	--
Gender				
- Male	223	84,456	37.2 (13.0)	0.06
- Female	109	35,722	39.6 (9.2)	
Age				
- 60 years or younger	133	45,155	40.1 (13.2)	0.003
- Over 60 years	199	75,023	36.5 (8.3)	
Number of registered subjects eligible for CRC screening (cluster size)				
- <250	66	11,147	41.5 (16.6)	0.023 <sup>A</sup>
- 250-349	66	19,998	36.2 (8.9)	0.019 <sup>B</sup>
- 350-449	132	53,375	39.0 (7.4)	<0.001 <sup>C</sup>
- ≥450	68	35,658	34.3 (8.9)	0.002 <sup>D</sup>
Geographical area				
- Senigallia	57	21,605	42.8 (9.1)	<0.001 <sup>E</sup>
- Jesi	74	25,314	43.7 (9.8)	<0.001 <sup>F</sup>
- Fabriano	31	10,741	39.5 (8.2)	0.041 <sup>G</sup>
- Ancona	170	62,518	33.5 (10.0)	<0.001 <sup>H</sup>

4  
5  
6  
7

CRC = colorectal cancer. GP = General Practitioner. SD = Standard deviation. \* Student's t test. <sup>A</sup> <250 vs. 250-349. <sup>B</sup> 250-349 vs. 350-449. <sup>C</sup> 350-449 vs. ≥450. <sup>D</sup> <250 vs. ≥450. <sup>E</sup> Senigallia vs. Ancona. <sup>F</sup> Jesi vs. Ancona. <sup>G</sup> Jesi vs. Fabriano. <sup>H</sup> Fabriano vs. Ancona. The remaining comparisons had p>0.05 and were not shown.

1

2 **Table 2.** Results of the random-effects linear regression predicting CRC screening uptake, with  
3 geographical area as the cluster variable.

4

<b>GP characteristics</b>	<b>Coefficient</b>	<b>(95% CI)</b>	<b>p*</b>
Male gender	1.06	(-0.44; 2.56)	0.17
Age (10-year decrease)	4.81	(3.73; 5.90)	<0.001
Number of assisted subjects eligible for CRC screening (100-subject decrease)	1.52	(0.40; 2.65)	0.008

5

6 CRC = colorectal cancer. GP = General Practitioner. CI = confidence interval. \* Two-tailed Wald  
7 test.

1  
2  
3  
4

**Table 3.** Results of the random-effects logistic regression predicting CRC screening uptake at or above the 45% acceptability threshold, with geographical area as the cluster variable.

<b>GP characteristics</b>	<b>OR</b>	<b>(95% CI)</b>	<b>p*</b>
Male gender	1.16	(0.62 - 2.18)	0.6
Age over 60 years (vs age 60 or less)	0.47	(0.27 - 0.84)	0.010
Number of registered subjects eligible for CRC screening (vs $\leq 250$ )			
- 250-349	0.41	(0.40 - 2.65)	0.071
- 350-449	0.40	(0.16 - 1.08)	0.20
- $\geq 450$	0.16	(0.07 - 0.37)	<0.001


5  
6  
7  
8

CRC = colorectal cancer. GP = General Practitioner. OR = Odds Ratios. CI = confidence interval.

\* Two-tailed Wald test.

1

2 **Figure 1.** Colorectal cancer screening organization in the Ancona province.



3

4 Notes: GP = General Practitioner. FIT = faecal immunochemical tests.


5 The dashed arrows represent the phases of the screening programme in which GP advice could  
6 improve uptake.

7

1

2 **Figure 2.** Bar graph showing GP cluster distribution by categories of 2018-19 CRC

3 screening uptake.



4

5 Notes: GP = General Practitioner. CRC = colorectal cancer.

6

7